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Abstract
Objective: To evaluate the actual perceptions of postmenopausal hormone therapy
(HT) in BRCA mutation carriers (BRCAmc) in comparison with women from the
general population.
Methods: Questionnaire‐based study of 83 BRCAmc and a control group of 89
women without a genetic mutation. Perceptions were evaluated by specific ques-
tions and Likert scales (−5–+5).
Results: Present and past users of HT were more frequent in the control group
(p = 0.01), with a longer time of use (p = 0.03). The preferred route of administration
of HT was ‘oral’ (54.6%). The most frequently reported adverse effect of HT was
venous thrombosis (0.8), while a protective effect on bone health was reported. No
noticeable beneficial effects of HT have been recognised for hot flushes (0.2) and
vaginal dryness (0.1). The most frequently perceived beneficial and adverse effects
of HT were not significantly different between BRCA mutation carriers and con-
trols. The greatest oncological fear was breast cancer (1.0). The protective role of
HT on colorectal cancer was not known (0.1). These oncological impacts were
mostly overestimated in BRCAmc, however this was not significant. Few BRCAmc
would think of taking HT after risk‐reducing surgeries.
Conclusions: Knowledge of the effects of HT on BRCAmc is relatively poor and they
are likely to overstate its negative effects and underestimate its health benefits;
however, this is not significant in comparison to the general population. More and
better information should be given to BRCAmc to allow them to make informed
decisions about the use of HT, especially before undergoing risk‐reducing surgeries.
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1 | INTRODUCTION
Postmenopausal hormone therapy (HT) is used to relieve menopausal
symptoms. It is the principal therapy for urogenital and vasomotor
symptoms of menopause.1 HT offers multiple additional beneficial
effects on women’s health: it has been approved by the Food and
Drug Administration (FDA) for the prevention and management of
osteoporosis.2 It also shows beneficial results on cognitive function
and, possibly, the prevention of dementia.2,3 Furthermore, as
confirmed by the Women’s Health Initiative (WHI) study, it can exert
a protective effect on the cardiovascular system if started at the
beginning of the menopause,1,2 and can also improve sleep and mood
disorders.2–5
Recent studies have demonstrated that this therapy can also
be safely used in women with a familial risk of breast and/or
ovarian cancer, such as BRCA1 and 2 mutation carriers. Short‐
term HT use has not been associated with an increased breast
cancer risk, in particular in women who have undergone previous
risk reducing mastectomy (RRM).6 Before the age of 51 and after
risk‐reducing salpingo‐oophorectomy (RRSO) and/or premature
ovarian insufficiency (POF), the benefits of HT overcome its risks,
if there are no contraindications.7 After the age of 51, it is
important to only treat women with debilitating vasomotor
symptoms, after alternative therapies have failed.7–12 For these
high‐risk patients, the decision to use HT is more complex and
should be discussed in detail before RRSO surgery. Some BRCA
mutation carriers undergoing RRSO are not candidates for HT due
to a personal history of breast cancer. For the remainder, the risks
of HT must be balanced with the impact of early menopause on
long‐term health and quality of life.11
There are different formulations for postmenopausal HT:
oestrogen only (indicated for women who have previously un-
dergone a hysterectomy), oestrogen combined with progestin
(indicated for women who did not have their uterus removed) and
also ‘progestin‐free’ drugs, such oral tibolone and combinations of
oestrogen with bazedoxifene (tissue selective oestrogen complex).7
HT can be taken at different doses and in different ways: orally,
as a patch, or as a transdermal or vaginal cream.2
Several studies in various countries have shown that women
have little knowledge of the menopause and the benefits and risks of
HT.13–21 However, there are currently no published studies evalu-
ating the awareness of the effects of HT in women at high‐risk of
developing breast and/or ovarian cancer, such as BRCA mutation
carriers.
The objective of this study is, therefore, to evaluate the current
knowledge of the benefits and risks of HT in women at high‐risk of
developing breast and/or ovarian cancer carrying a BRCA mutation,
also assessing the main concerns about taking such therapy, in
comparison with the responses of women from the general
population.
2 | METHODS
2.1 | Study design
This is a cross‐sectional, observational study performed from
December 2019 to May 2020 at Modena family cancer clinic (MFCC),
one of four hub centres of our region (Emilia‐Romagna), which
identifies families with increased hereditary cancer risk. Post-
menopausal women with a pathogenic germline BRCA mutation were
recruited (both naturally and surgically‐occurred menopause). A
control group of women without a genetic mutation was obtained
from a group of postmenopausal subjects with no previous onco-
logical diseases evaluated for a routine visit at the general gynae-
cological service of the same hospital in April and May 2020
(‘Ambulatorio Divisionale’). This service is where general practi-
tioners send patients for routine gynaecological examinations.
Therefore, they are healthy women who did not present particular
gynaecological disorders or complaints. The menopausal status was
classified as amenorrhoea longer than 12 months.
2.2 | Evaluated variables
During the routine gynaecological examination, clinical data of
included women were collected: age, parity, number of vaginal or
caesarean births, abortions, and gynaecological (hysterectomy
salpingo‐oophorectomy [RRSO]) and breast (mastectomy, quad-
rantectomy, risk‐reducing mastectomy [RRM]) surgeries previously
performed. After a detailed counselling session about the study, the
woman who chose to participate signed an informed consent. Once
included in the study, women were given a different questionnaire
depending on the group they belonged to (with and without genetic
mutation; Table S1).
For both groups of women (with and without mutation), ques-
tionnaires collected data on the type of HT used (oral, transdermal,
vaginal cream), the brand name of the product used, and the use
(current, past, and never used) and duration of use (months/years).
Women were asked to evaluate, in their opinion, how much HT could
affect the risk of developing some types of cancer (breast, ovary,
colon, uterine body and uterine cervix), or diseases (venous throm-
bosis, breast cysts, osteoporosis, bone fractures, cardiovascular dis-
eases, early dementia and depression), or classical menopausal
symptoms (headache, weight gain, reduced sexual desire, vaginal
dryness, dyspareunia, increased appetite, mood swings, hot flashes,
sleep disturbances and urinary incontinence) using a Likert scale
from −5 to +5. For cancers and diseases, the following values were
used: −5 = reduces the risk of onset, 0 = has a neutral effect,
+5 = increases the risk of onset, while for symptoms the following
values were applied: −5 = worsens with HRT, 0 = neutral effect, and
+5 = improves with HT (Table S1).
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Participants’ preferences regarding the different routes of
administration of HT, their opinion concerning the quality of the in-
formation they were provided with by health care providers (HCP),
their use of a hormonal contraceptive method in the past (present or
past users) and, if so, which one and for how long (months/years)
were also evaluated.
Only in the group of women with a genetic mutation, whether
they would take the therapy after a RRSO and/or RRM and how
safe they would feel taking HT was asked using a visuo‐analogue
scale (VAS) from 0 to 10 (0 = very insecure, 10 = very safe).
Specific questionnaires used in this study for women with and
without mutation are reported in Table S1 in the English trans-
lation. We used the same questionnaires applied in a recent Italian
study22 and validated the simple questions in a previous pilot
evaluation.
2.3 | Ethics and statistics
The results of this study are part of a larger project named ‘Quality
of (reproductive) life in women at increased risk of hereditary and/
or ovarian cancer’ approved by the Area Vasta Emilia Nord Ethics
Committee (Reference No. 515, 2019). The primary endpoint of
this larger trial will be to study the type and intensity of climac-
teric symptoms, the reduced quality of life, sexual and mental
health, and alterations in bone mineral density and biomarkers of
cardiovascular disease, in BRCA mutation carriers according to
RRSO status and timing. A specific informed consent was obtained
from each woman for the use of her personal data in the research
analysis.
The answers of women with and without mutation were
analysed and compared. The prevalence in the different groups
was calculated. When necessary, the prevalence was compared by
means of contingency tables. Comparisons between groups for
continuous variables were performed by Student's test. Results of
the VAS from 0 to 10 (0 = very insecure, 10 = very safe) were
categorised as 0–3: low, 4–7: medium, and 8–10: high. The sta-
tistical analysis was performed using the statistical package Stat-
View (v 5.01.98; SAS Institute Inc., Cary, NC). Correlations were
considered significant at a p‐value <0.05. The results of the
continuous data are expressed as the mean ± standard deviation
(SD).
2.4 | Sample size calculation
Assuming a pooled SD of 1 unit, the study would require a sample size
of 63 women for each group (i.e., a total sample size of 126, assuming
equal group sizes), to achieve a power of 80% and a level of significance
of 5% (two sided), for detecting a true difference in means of 0.5 unit in
some Likert Scale values between different groups.
3 | RESULTS
3.1 | Study group
A population of 172 women (mean age: 54.4 ± 7.0 years, range
37.9–74.0 years) was included in the study and completed the
specific questionnaires. Of these women, 89 (51.7%) did not have
any known genetic mutation (control group), while 83 (48.3%)
were BRCA mutation confirmed carriers (BRCA1: 42 [50.6%],
BRCA2: 41 [49.4%]) of a similar age. The features of the included
women are shown in Table 1. There were only 19/172 (11.0%)
present users of HT in the whole group are at the time of study
inclusion: present and past users of HT were more frequent in the
control group (p = 0.01), with a longer time of use (p = 0.03). The
rate of women who had already undergone RRSO in mutation
carriers was 42/83 (50.6%), while those with previous RRM was
11/83 (13.3%).
The preferred route of administration of an eventual HT was oral
in 94/172 (54.6%) women, transdermal by a patch in 56/172 (30.2%)
women and vaginal by a cream in 20/172 (11.6%) women; the choice
was not different between BRCA mutation carriers and the control
group: oral (60% vs. 49%), transdermal (29% vs. 36%) and vaginal (8%
vs. 15%; p = 0.23).
3.2 | Knowledge of effects of hormone therapy on
diseases development and on menopausal symptoms
The answers to the questions ‘How much can HT increase or reduce
the risk of developing these diseases?’ and ‘How much can HT
improve or worsen these symptoms?’ are reported in Table 2 for the
whole study group and for BRCA mutation carriers versus the control
group separately.
The most commonly reported adverse effect associated with
HT was venous thrombosis (0.8 ± 0.2), followed by the develop-
ment of breast cysts (0.7 ± 0.2). A protective role of HT was re-
ported for bone fracture (−0.9 ± 0.2), osteoporosis (−0.7 ± 0.2),
depression (−0.6 ± 0.2) and dementia (−0.4 ± 0.2). However, these
effects were generally underestimated (<1 out of 5 of possible
Likert Scale), especially in BRCA mutation carriers, although these
results were not statistically significant (p > 0.05; Table 2). Inter-
estingly, the most significant side effects of HT were weight in-
crease (0.7 ± 0.2), headache (0.5 ± 0.2) and increased appetite
(0.3 ± 0.2). The impact of these was generally overestimated in
mutation carriers. No particular beneficial effect of HT was recog-
nised for hot flushes (0.2 ± 0.3), mood swings (0.1 ± 0.2), sleep
disorders (0.1 ± 0.2) and vaginal dryness (0.1 ± 0.2), if not sub-
stantially neutral. This was confirmed for both BRCA mutation
carriers and the control group. These answers were not statistically
different in the BRCA mutation carrier females with and without
previous RRSO or RRM (p > 0.05).
GRANDI ET AL. - 3
TAB L E 1 Features of n = 172 women included in the study with or without BRCA gene mutation
BRCA mutation carriers (n = 83) Control group (n = 89) p
Mutation type BRCA1: 42 (50.6%) / ‐
BRCA2: 41 (49.4%) / ‐
Age (years old) 55.0 ± 8.2 53.9 ± 5.9 0.3
Nulliparous (n, %) 11 (13.3%) 14 (15.7%) 0.65
HT use (n, %)
Present users 6 (7.2%) 13 (14.6%) 0.01
Past users 6 (7.2%) 17 (18.9%) ‐
Never 71 (85.6%) 59/89 (66.3%) ‐
Duration of use (months) 17.1 ± 17.2 41.7 ± 50.2 0.03
Past hormonal contraceptives users 52 (62.7%) 65 (73%) 0.12
Abbreviation: HT; postmenopausal hormone therapy.
TAB L E 2 Mean ± Standard error (Likert scale from −5 to +5) sort in descending order to the questions ‘How much can HT increase or
reduce the risk of developing these diseases?’ and ‘How much can HT improve or worsen these symptoms?’ for the whole study group in
comparison with what emerges from the literature (in the general population) and for BRCA mutation carriers versus control group
separately






carriers (n = 83)
Control group
(n = 89) p
Venous thrombosis 0.8 ± 0.2 Increased risk 0.9 ± 0.2 0.6 ± 0.3 0.52
Breast cysts 0.7 ± 0.2 Increased risk 1.0 ± 0.2 0.5 ± 0.3 0.32
Cardiovascular diseases 0.1 ± 0.2 Reduced risk 0.4 ± 0.3 −0.2 ± 0.2 0.16
Dementia −0.4 ± 0.2 Uncertain −0.2 ± 0.2 −0.5 ± 2.6 0.39
Depression −0.6 ± 0.2 Uncertain −0.4 ± 0.3 −0.7 ± 0.2 0.16
Osteoporosis −0.7 ± 0.2 Reduced risk −0.4 ± 0.3 −1.0 ± 0.3 0.14
Bone fractures −0.9 ± 0.2 Reduced risk −0.5 ± 0.3 −1.2 ± 0.3 0.09
How much does HT improve or worsen these symptoms?
Weight increase 0.7 ± 0.2 Uncertain 1.2 ± 0.3 0.3 ± 0.4 0.07
Headache 0.5 ± 0.2 Uncertain 1.0 ± 0.2 0.2 ± 0.3 0.05
Increased appetite 0.3 ± 0.2 Uncertain 0.6 ± 0.2 0.0 ± 0.3 0.14
Hot flashes 0.2 ± 0.3 Reduced risk 0.4 ± 0.3 0.1 ± 0.4 0.57
Mood swings 0.1 ± 0.2 Reduced risk 0.4 ± 0.3 −0.1 ± 0.3 0.2
Sleep disorders 0.1 ± 0.2 Uncertain 0.3 ± 0.3 0.0 ± 0.3 0.42
Vaginal dryness 0.1 ± 0.2 Reduced risk 0.2 ± 0.3 0.0 ± 0.4 0.68
Dyspareunia 0.0 ± 0.2 Reduced risk −0.1 ± 0.2 0.0 ± 0.3 0.87
Reduction of libido −0.1 ± 0.2 Reduced risk 0.1 ± 0.3 −0.3 ± 0.3 0.41
Urinary incontinence −0.2 ± 0.2 Reduced risk 0.2 ± 0.2 −0.5 ± 0.3 0.09
Abbreviation: HT; postmenopausal hormone therapy.
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3.3 | Knowledge of effects of hormone therapy on
cancer development
For the analysis of this specific topic, we decided to exclude the
considerable group of breast and ovarian cancer survivors in the
BRCA mutation carriers group (n = 29 [34.9%], past breast cancer
n = 25, past ovarian cancer n = 3 and past ovarian and breast cancer
n = 1).
The answers to the question ‘How much can HT increase or
reduce the risk of developing these cancers?’ are shown in Table 3.
The greatest concern was about breast cancer (1.0 ± 0.3)
followed by ovarian cancer (0.5 ± 0.2), uterine body cancer
(0.4 ± 0.2) and uterine cervix cancer (0.4 ± 0.2). The protective
role of HT against colorectal cancer was not known (0.1 ± 0.2).
These effects were generally overestimated in BRCA mutation
carriers, although the results were not statistically significant
(p > 0.05; Table 3).
3.4 | Counselling quality of health care providers
and willingness to initiate hormone therapy after risk‐
reducing salpingo‐oophorectomy/ risk‐reducing
salpingo‐oophorectomy
Overall, most women (102/172, 59.3%) stated that they received
adequate information about HT, with similar results in BRCA muta-
tion carriers versus the control group. The percentage of women who
considered the information received to be inadequate was signifi-
cantly lower in women who had never used HT in comparison to
those who used HT (50.8% vs. 85.7%; p < 0.0001). Our analysis
shows that the majority of BRCA mutation carriers (67.5%) are
worried that the use of HT may increase their risk of developing
cancer (Figure 1).
Indeed, in mutation carriers the willingness to take HT was
generally very low and no significantly different emerged after under-
going any of the two risk‐reducing surgeries, RRSO or RRM (mean
3.4 ± 0.4 vs. 3.5 ± 0.4 VAS, p = 0.81, rate in Figure 2).
4 | DISCUSSION
4.1 | Main results
The results of the present study demonstrate that, in women at high
risk of developing breast and ovarian cancer, the knowledge of
menopausal symptoms and possible HT beneficial effects is relatively
low. BRCA mutation carriers are likely to overstate the negative ef-
fects of HT and underestimate its health benefits. It should be
pointed out, however, that we did not find substantial differences in
their perceptions in comparison to the general population.
Therefore, it is essential to raise awareness regarding meno-
pausal symptoms and management options, not only in the general
population, but also in the high‐risk group. The rate of use of post-
menopausal HT is very low in our sample (11.0%), and was mainly
reported in women without a BRCA mutation.
The most frequently reported HT‐related adverse effect was
venous thrombosis. On the other hand, with a similar potency, a
protective effect on bone, depression and dementia was reported.
Interestingly, less is known about the classical favourable effects on
hot flushes, mood swings, sleep disorders and vaginal dryness ach-
ieved with HT use, also in women from the general population.
The greatest fear on the oncological side was, as expected, breast
cancer, especially in this high‐risk population. Concomitantly, the
protective role of HT use on colorectal cancer was not properly
understood. BRCA mutation carriers tended to report an over-
estimation of the carcinogenetic risks associated with HT, although
this was not significant.
Overall, detailed information tends to increase the willingness to
use HT: nevertheless, few BRCA mutation carriers would think of
taking HT after risk‐reducing surgeries, similarly after RRSO or RRM.
4.2 | Clinical implications
HT use has declined by up to 62% since the publication of WHI
study.23,24 Our data indicate that education about the effects of HT
TAB L E 3 Mean ± Standard error (Likert scale from −5 to +5) sort in descending order to the question ‘How much can HT increase or
reduce the risk of developing these cancers?’ for the whole study group in comparison with what emerges from the literature (in the general
population) and for BRCA mutation carriers versus control group separately
How much does HT increase or reduce the risk of developing these cancers?
Total group (n = 143) Evidence from the literature BRCA mutation carriers (n = 54) Control group (n = 89) p
Breast cancer 1.0 ± 0.3 Increased risk 1.1 ± 0.3 0.9 ± 0.4 0.63
Ovarian cancer 0.5 ± 0.2 Increased risk 0.7 ± 0.3 0.4 ± 0.3 0.53
Uterine body cancer 0.4 ± 0.2 Neutral effect 0.6 ± 0.3 0.4 ± 0.3 0.60
Uterine cervix cancer 0.4 ± 0.2 Neutral effect 0.8 ± 0.3 0.3 ± 0.3 0.33
Colorectal cancer 0.1 ± 0.2 Reduced risk 0.3 ± 0.3 −0.1 ± 0.3 0.31
Abbreviation: HT; postmenopausal hormone therapy.
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F I GUR E 1 Most important concerns and fears (%) in relation to postmenopausal hormone therapy use reported by BRCA mutation
carriers
F I GUR E 2 Willingness to take postmenopausal hormone therapy (HT) after undergoing risk‐reducing surgeries in BRCA mutation carriers
(visuo‐analogic scale [VAS] from 0 to 10 [0 = very insecure, 10 = very safe] categorized as 0–3: low, 4–7: medium and 8–10: high). RRM, risk‐
reducing mastectomy; RRSO, risk‐reducing salpingo‐oophorectomy
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should be further improved and, in daily practice, myths and taboos
regarding side effects and long‐term consequences of HT use on
women’s health need to be fully addressed. For example, these
women are still not aware of the protective action of HT against
colorectal cancer,13 as demonstrated in another Italian trial for
combined hormonal contraceptives (CHCs).22 Colorectal cancer is
the most frequent neoplasm in non‐smokers of both sexes combined
in Western countries. Oestrogens may exert an anti‐tumour effect
through the selective activation of pro‐apoptotic signalling mediated
by oestrogen receptor (ER)‐β, the inhibition of inflammatory signals
and modulation of the tumour microenvironment. HT use, as for CHC
use, acts as a protective factor for this widespread cancer.25 Poor
knowledge of the positive effects of hormones on carcinogenic risks
was recently demonstrated for CHCs, given that very few women
correctly identified the potential reduction of ovarian and endome-
trial cancer risk for CHCs.26 The cancer potential associated with HT
is overestimated, especially in BRCA genetic mutation carriers, and,
most importantly, for breast cancer.17 Real numbers teach us that
combined oestro‐progestin therapy, particularly with synthetic pro-
gestins, is associated with an increased risk of breast cancer of 8
women per 1,000 women per 5 years. In contrast, use of oestrogens
alone for less than 5 years may reduce the risk of breast cancer.
Long‐term oestrogen‐alone therapy is associated with a very small
attributable risk of ovarian cancer of 0.7 woman per 1000 women
per 5 years of use.27 This low attributable risk must however be
taken into consideration in this specific very high risk population
because ovarian cancer maintains a high intrinsic malignancy and
high recurrence rate after surgery and first line chemotherapy.28,29
Balanced oestro‐progestin administration abrogates the effect of
oestrogen and does not cause an increase in endometrial cancer.
Attitudes of HCPs may contribute significantly to women’s knowl-
edge, depending on their ability to share conclusive information with
potential users, especially in the hereditary cancer population.
Interestingly, less is known about the classical favourable effects
on vasomotor symptoms and vaginal dryness achieved with HT use.
In our study, women had a very low perception that HT can reduce
vasomotor symptoms, a fact that was also reported in studies per-
formed in a general population from Europe,14 in Chinese women
from Hong Kong30 and from the United Arab Emirates.13 This is
surprising since the improvement of vasomotor symptoms is the best
recognised and most immediate effect of HT, also in absolute terms.
HT can diminish symptoms of hot flushes and vaginal atrophy in 800–
900 out of 1000 users per 5 years of use, while causing only 8 extra
cases of breast cancer or of venous thrombosis in the same group of
women.27 However, in our study, the perceived Likert risk is +0.1/0.2
(out of −5 to +5) for the climacteric symptoms and +0.8/1 for breast
cancer and venous thrombosis.
Ultimately, we observed a better understanding of the beneficial
effects of HT on the risk of bone fractures and osteoporosis as in other
published trials form the general population,16 and in contrast to a
Belgian study in which osteoporosis was not perceived to be a more
important disease by women with HT experience than by those
without such experience.31
The majority of women of our population (54.6%), and also in
BRCA mutation carriers, preferred the oral administration of HT. This
is in line with other trials and demonstrates a higher level of
compliance for oral HT formulations,32,33 although this route of
administration is associated with a greater thromboembolic risk
compared to the transdermal administration.34
In our Institution, we have decided to treat, in accordance with
oncologists and breast surgeons, all BRCA mutation carriers younger
than 51 years of age after RRSO and/or premature ovarian insuffi-
ciency (POF). After 51 years of age, we commonly treat only women
with important vasomotor symptoms, after the failure of alternative
therapies. Oestrogen‐only therapy plays a key role in hysterectom-
ised women. In the case of an intact uterus, associations with the
lowest dose of progestins/natural progesterone derivatives have to
be preferred, as progestins has been shown to play an important role
in BC transformation, especially in BRCA1 mutation carriers.7 In the
case of an intact uterus, associations with the lowest dose of pro-
gestins/natural progesterone derivatives have to be preferred, as
progestins have been shown to play an important role in breast
cancer transformation, especially in BRCA1 mutation carriers. More
and better information should be given to allow to make informed
decisions about their health status in menopause and the use of HT.
For women requesting HT, physicians may consider informing women
that climacteric symptoms may be short‐lasting and benign and
should be aware of the balanced effectiveness and risks of HT based
on each individual situation. Unfortunately, most women with a
BRCA mutation in our study reported that they would not consider
taking HT even after risk‐reducing surgery. However, separate data
from our MFCC have shown a higher rate of actual use of HT after
RRSO in women with vasomotor symptoms using our approach to
counsel women with BRCA mutations.35
The data presented here also suggest that a specific information
leaflet summarising the major benefits, risks and side effects of the
HT in the context of hereditary cancer would be valuable for women
at risk and doctors who care for them.
4.3 | Study limitations
There were several limitations to the survey, including its cross‐
sectional study design and representativeness of the sample. This is
not a randomly selected population. Recruiting participants directly
from the MFCC and other gynaecological hospital services might have
biased the sample by including participants with relatively high health
beliefs and those who are better motivated to co‐operate with HCPs in
screening policies. Moreover, our sample size calculation was able to
recognise a true difference in the form of 0.5 units in some Likert Scale
values between different groups, BRCA mutation carriers versus
controls. However, it would be not large enough to enable the possible
detection of negligible differences <0.5 points between different
groups. Furthermore, power calculations were not helpful in the sub‐
analysis about knowledge of effects of HT on cancer development
because we later removed the cancer survivors as they might have
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overestimated the oncological risks related to HT. Ultimately, women
in the younger age range were not included in the analysis despite the
need to clarify the issues in relation to hormonal contraceptives in this
group. However, a study is currently ongoing which focusses on this
important group and data will be reported in due course.
The strengths of this study include the presence of a control
group without a genetic mutation, the in‐depth queries in our ques-
tionnaires and the availability of large amounts of data from partic-
ipants. Moreover, the age distribution between the two included
groups was similar.
5 | CONCLUSIONS
Knowledge of the possible beneficial effects of HT is relatively low in
BRCA mutation carriers, as in the general population, and they are
likely to overstate its negative effects and underestimate its health
benefits. More and better information should be given to these high‐
risk women to allow them to make informed decisions about the use
of HT, especially before undergoing risk‐reducing surgeries.
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